+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Antivirals Global Market Report 2020

  • ID: 4856006
  • Report
  • November 2019
  • Region: Global
  • 200 pages
  • The Business Research Company

Enquire about COVID-19 updates for this product.

Enquire Now

FEATURED COMPANIES

  • Abbott Healthcare
  • Bristol-Myers-Squibb
  • F. Hoffmann-La Roche AG
  • Johnson & Johnson
  • Mylan N.V.
  • Roche Holding AG
  • MORE
Antivirals Market Global Report 2020 from the author provides strategists, marketers and senior management with the critical information they need to assess the global antivirals market.

Reasons to Purchase
  • Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market research findings.
  • Benchmark performance against key competitors.
  • Utilize the relationships between key data sets for superior strategizing.
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis
  • Report will be updated with the latest data and delivered to you within 3-5 working days of order.
Description:
Where is the largest and fastest growing market for the antivirals? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The Antivirals Market Global Report from the author answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market
  • The Market Characteristics section of the report defines and explains the market.
  • The Market Size section gives the market size ($b) covering both the historic growth of the market and forecasting the future. Drivers and restraints looks at the external factors supporting and controlling the growth of the market.
  • Market Segmentations break down market into sub markets.
  • The Regional and Country section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers all the regions, key developed countries and major emerging markets. It draws comparisons with country populations and economies to understand the importance of the market by country and how this is changing.
  • Competitive Landscape gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
  • The Trends and Strategies section highlights the likely future developments in the market and suggests approaches companies can take to exploit this.
Scope
  • Markets Covered: 1) By Therapeutics: HIV/AIDS Therapeutics, Hepatitis (B & C) Therapeutics, Herpes Therapeutics, Influenza Therapeutics, Others (Pneumonia) 2) By End User: Hospitals, Clinics, Ambulatory surgical center 3) By Target: DNA polymerase, NS3 Protease, Reverse transcriptase, Others 4) By Drug Type: Generic, Branded
  • Companies Mentioned: Merck & Co. Inc., Johnson & Johnson, GlaxoSmithKline Plc, Roche Holding AG , Gilead Sciences
  • Countries: Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA
  • Regions: Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
  • Time Series: Five years historic and forecast.
  • Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
  • Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • Abbott Healthcare
  • Bristol-Myers-Squibb
  • F. Hoffmann-La Roche AG
  • Johnson & Johnson
  • Mylan N.V.
  • Roche Holding AG
  • MORE
1. Executive Summary

2. Antivirals Market Characteristics

3. Antivirals Market Size And Growth
3.1. Global Antivirals Historic Market, 2015 - 2019, $ Billion
3.1.1. Drivers Of The Market
3.1.2. Restraints On The Market
3.2. Global Antivirals Forecast Market, 2019 - 2022F, 2025F, 2030F, $ Billion
3.2.1. Drivers Of The Market
3.2.2. Restraints On the Market

4. Antivirals Market Segmentation
4.1. Global Antivirals Market, Segmentation By Therapeutics, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion
  • HIV/AIDS Therapeutics Hepatitis (B & C) Therapeutics
  • Herpes Therapeutics Influenza Therapeutics
  • Others (Pneumonia)
4.2. Global Antivirals Market, Segmentation By End User, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion
  • Hospitals Clinics
  • Ambulatory surgical center
4.3. Global Antivirals Market, Segmentation By Target, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion
  • DNA polymerase NS3 Protease
  • Reverse transcriptase Others
4.4. Global Antivirals Market, Segmentation By Drug Type, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion
  • Generic Branded
5. Antivirals Market Regional And Country Analysis
5.1. Global Antivirals Market, Split By Region, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion
5.2. Global Antivirals Market, Split By Country, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion

6. Asia-Pacific Antivirals Market
6.1. Asia-Pacific Antivirals Market Overview
6.2. Asia-Pacific Antivirals Market, Segmentation By Therapeutics, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion
6.3. Asia-Pacific Antivirals Market, Segmentation By End User, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion

7. China Antivirals Market
7.1. China Antivirals Market Overview
7.2. China Antivirals Market, Segmentation By Therapeutics, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F,$ Billion
7.3. China Antivirals Market, Segmentation By End User, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F,$ Billion

8. India Antivirals Market
8.1. India Antivirals Market Overview
8.2. India Antivirals Market, Segmentation By Therapeutics, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion
8.3. India Antivirals Market, Segmentation By End User, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion

9. Japan Antivirals Market
9.1. Japan Antivirals Market Overview
9.2. Japan Antivirals Market, Segmentation By Therapeutics, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion
9.3. Japan Antivirals Market, Segmentation By End User, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion

10. Australia Antivirals Market
10.1. Australia Antivirals Market, Segmentation By Therapeutics, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion
10.2. Australia Antivirals Market, Segmentation By End User, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion

11. Indonesia Antivirals Market
11.1. Indonesia Antivirals Market, Segmentation By Therapeutics, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion
11.2. Indonesia Antivirals Market, Segmentation By End User, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion

12. South Korea Antivirals Market
12.1. South Korea Antivirals Market, Segmentation By Therapeutics, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion
12.2. South Korea Antivirals Market, Segmentation By End User, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion

13. Western Europe Antivirals Market
13.1. Western Europe Antivirals Market Overview
13.2. Western Europe Antivirals Market, Segmentation By Therapeutics, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion
13.3. Western Europe Antivirals Market, Segmentation By End User, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion

14. UK Antivirals Market
14.1. UK Antivirals Market Overview
14.2. UK Antivirals Market, Segmentation By Therapeutics, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion
14.3. UK Antivirals Market, Segmentation By End User, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion

15. Germany Antivirals Market
15.1. Germany Antivirals Market, Segmentation By Therapeutics, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion
15.2. Germany Antivirals Market, Segmentation By End User, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion

16. France Antivirals Market
16.4. France Antivirals Market, Segmentation By Therapeutics, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion
16.5. France Antivirals Market, Segmentation By End User, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion

17. Eastern Europe Antivirals Market
17.1. Eastern Europe Antivirals Market Overview
17.2. Eastern Europe Antivirals Market, Segmentation By Therapeutics, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion
17.3. Eastern Europe Antivirals Market, Segmentation By End User, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion

18. Russia Antivirals Market
18.1. Russia Antivirals Market, Segmentation By Therapeutics, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion
18.2. Russia Antivirals Market, Segmentation By End User, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion

19. North America Antivirals Market
19.1. North America Antivirals Market Overview
19.2. North America Antivirals Market, Segmentation By Therapeutics, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion
19.3. North America Antivirals Market, Segmentation By End User, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion

20. USA Antivirals Market
20.1. USA Antivirals Market Overview
20.2. USA Antivirals Market, Segmentation By Therapeutics, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion
20.3. USA Antivirals Market, Segmentation By End User, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion

21. South America Antivirals Market
21.1. South America Antivirals Market Overview
21.2. South America Antivirals Market, Segmentation By Therapeutics, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion
21.3. South America Antivirals Market, Segmentation By End User, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion

22. Brazil Antivirals Market
22.1. Brazil Antivirals Market, Segmentation By Therapeutics, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion
22.2. Brazil Antivirals Market, Segmentation By End User, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion

23. Middle East Antivirals Market
23.1. Middle East Antivirals Market Overview
23.2. Middle East Antivirals Market, Segmentation By Therapeutics, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion
23.3. Middle East Antivirals Market, Segmentation By End User, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion

24. Africa Antivirals Market
24.1. Africa Antivirals Market Overview
24.2. Africa Antivirals Market, Segmentation By Therapeutics, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion
24.3. Africa Antivirals Market, Segmentation By End User, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion

25. Antivirals Market Competitive Landscape And Company Profiles
25.1. Antivirals Market Competitive Landscape
25.2. Antivirals Market Company Profiles
25.2.1. Merck & Co. Inc.
25.2.1.1. Overview
25.2.1.2. Products and Services
25.2.1.3. Strategy
25.2.1.4. Financial Performance
25.2.2. Johnson & Johnson
25.2.2.1. Overview
25.2.2.2. Products and Services
25.2.2.3. Strategy
25.2.2.4. Financial Performance
25.2.3. GlaxoSmithKline Plc
25.2.3.1. Overview
25.2.3.2. Products and Services
25.2.3.3. Strategy
25.2.3.4. Financial Performance
25.2.4. Roche Holding AG
25.2.4.1. Overview
25.2.4.2. Products and Services
25.2.4.3. Strategy
25.2.4.4. Financial Performance
25.2.5. Gilead Sciences
25.2.5.1. Overview
25.2.5.2. Products and Services
25.2.5.3. Strategy
25.2.5.4. Financial Performance

26. Key Mergers And Acquisitions In The Antivirals Market

27. Antivirals Market Trends And Strategies

28. Product Pipeline Analysis

29. Antivirals Market Future Outlook and Potential Analysis

30. Appendix
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • Abbott Healthcare
  • Bristol-Myers-Squibb
  • F. Hoffmann-La Roche AG
  • Johnson & Johnson
  • Mylan N.V.
  • Roche Holding AG
  • MORE
The antivirals market consists of sales of antiviral drugs and related services. Antiviral drugs reduces the replication of viruses at different stages. Various type of viral infections for which antiviral drugs are used include HIV, herpes, hepatitis and influenza viruses.

The global antivirals market was valued at about $38.1 billion in 2018 and is expected to grow to $52.22 billion at a CAGR of 8.2% through 2022.

The antivirals market has been geographically segmented into North America, Western Europe, APAC, Eastern Europe, South America and Middle East & Africa. The North American market is the largest market for antivirals and is expected to continue to be the largest market during the forecast period

The rising incidents of viral infections across the world is a significant driver for the antiviral drugs market. A virus is a small infectious agent which has the ability to invade a host cell and then grow in multiple numbers. Viruses can originate through various sources such as unhygienic living condition, change in weather or direct physical contact (body fluids and touch) with any host that is already infected with virus. According to UNAIDS, as of 2017, 36.9 million people were affected with HIV globally and out of those around 1.8 million people were affected with HIV in 2017.

The rising incidents of antiviral resistance is one of the major restraints for the antiviral drug market. Antiviral resistance occurs when viruses mutate and adapt to antiviral drugs due to prolonged usage of these drugs. The mutation changes that parts of the virus-cell that are affected by drugs, thus causing the antiviral drug to become ineffective against the virus. For example, in June 2017, the WHO (World Health Organization) removed Oseltamivir antiviral drug from the list of its essential medicines due to the drug's low effectiveness. Oseltamivir was used to cure flu virus (Influenza). Similarly, another class of drug, Adamantanes, which includes Amantadine (Symadine) and Rimantadine (Flumadine) were reported by CDC (Centers for Disease Control and Prevention) in the year 2017-18 as an ineffective medication, due to increase in resistance by Influenza A strains like H1N1 and H3N2 Viruses.

Pharmaceutical companies are increasingly using combination therapy to develop antiviral drugs to boost their effectiveness against viral infections. Combination therapy combines more than one medication for the treatment of the same condition. Combination therapy is beneficial in case if viral organisms like the influenza virus, develops resistance to a particular antiviral drug. However, it takes longer for the virus to develop resistance to a combination of drugs which are used together. In combination therapy, it is ensured that the viral infections are receptive to at least one of the drugs, which terminates replication and suppresses the infection. Combination therapy is especially helpful in the treatment of HIV as they help to combat the other infections which arise out of HIV. In 2018, Cocrystal Pharma, Inc., a biotechnology company which discovers and develops novel antiviral therapeutics, announced a Clinical Trial Agreement for investigator-initiated Phase 2a study of their new drug, CC-31244. This drug in combination with Sofosbuvir (direct acting antiviral medication used as part of combination therapy to treat chronic Hepatitis C) and Daclatasvir (medication used in synthesis with other medications to treat hepatitis C) will be used in the treatment of hepatitis C.

The Center for Drug Evaluation and Research, under Food and Drug Administration (FDA), provides guidance and recommendations for companies which manufacture antivirals drugs. For instance, under FDA guidance, the drugs for RHL (cold sores) undergo phase I safety studies, after which the proof-of-concept and dose-ranging are carried out in phase II studies. Finally, the drug has to undergo phase III superiority trials, which shows that one treatment is superior to another after which the approval is given.

Roche, a Swiss based pharmaceutical company, is set to acquire the US based Spark therapeutics, for USD 4.3 Billion. The deal is expected to be completed in June 2019. Roche through this acquisition will try to use gene therapy to develop new antivirals with high effectiveness. Spark, a US based biotechnology company, was found in 2013 and is widely popular due to advanced its advances in gene therapy drugs.

Major players in the market are Merck & Co. Inc., Johnson & Johnson, GlaxoSmithKline Plc, Roche Holding AG and Gilead Sciences.
Note: Product cover images may vary from those shown
  • Merck & Co. Inc.
  • Johnson & Johnson
  • GlaxoSmithKline Plc
  • Roche Holding AG
  • Gilead Sciences
  • Bristol-Myers-Squibb
  • F. Hoffmann-La Roche AG
  • AbbVie Inc.
  • Cipla Inc.
  • Pfizer Inc.
  • Dr Reddy
  • Med Immune/AstraZeneca
  • Abbott Healthcare
  • Roche Holding AG
  • Novartis International AG
  • Schering-Plough
  • Teva Pharmaceutical Industries Ltd.
  • Mylan N.V.
  • Sanofi
  • Aurobindo Pharma
Note: Product cover images may vary from those shown

Loading
LOADING...

Adroll
adroll